Kaiku Health has taken its first steps to tackle the big issue related to the challenge of identifying which patients are likely to benefit from immune checkpoint inhibitor (ICI) therapies. The unfortunate fact is that not all eligible patients respond to these therapies at all, and for some of those who have a response, it...
Kaiku Health, together with Oulu University Hospital, will present research at the ESMO Immuno-Oncology Congress 2020, which takes place as a virtual conference this year. The research investigates the use of Machine Learning to predict the objective response rate in immune checkpoint inhibitor treated patients when patient-reported and clinical data data are used as input...
Kaiku has continued its work among building machine learning (ML) based prediction models for immunotherapy-related symptom development. A year ago results from the first study were presented in the ESMO IO congress 2019 where it was showcased that ML based modeling of ePRO data on ICI treated cancer patients is feasible in predicting the onset...
Kaiku Health, the developer of digital health intervention platform in oncology, has received the Digi-HTA recommendation of use. The Digi-HTA is a criteria tool for assessing digital healthcare services’ (eg. mobile apps, AI solutions, and robotics) suitability for use in healthcare. The recommendation states that: “The Kaiku Health service is suitable for monitoring the well-being...
Increasing the understanding behind treatment response and immune-related adverse events in cancer patients treated with immune checkpoint inhibitor therapies Kaiku Health and Oulu University Hospital (OYS) aim to increase the understanding behind treatment benefit and onset of complex immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapies. The findings from this study conducted...